Search for content, post, videos

BioInvent announces a fourth complete response in Phase 1/2 trial

BioInvent International has announced that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma (NHL). Th
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.